International journal of cancer · 2024
Comprehensive genomic profiling of salivary gland carcinoma: Analysis of the Center for Cancer Genomics and Advanced Therapeutics database in Japan.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Iwaki Sho, Kawakita Daisuke, Nagao Toshitaka, Tada Yuichiro, Honma Yoshitaka, Ando Mizuo, Matoba Takuma, Minohara Kiyoshi, Nakano Satsuki, Murase Takayuki, Iwasaki Shinichi, Inagaki Hiroshi
Аннотация
Comprehensive information on genetic alterations in salivary gland cancer (SGC) is limited. This study aimed to elucidate the genetic and clinical characteristics of patients with SGC using the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, a Japanese national genomic database. We analyzed data of 776 patients with SGC registered in the C-CAT database between June 1, 2019, and June 30, 2023. Adenoid cystic carcinoma was the most common histologic type, followed by salivary duct carcinoma (SDC) and adenocarcinoma not otherwise specified. Genetic data of 681 patients receiving FoundationOne® CDx were analyzed. We identified specific features of the combination of TP53 and CDKN2A alterations among the histological types. Specific LYN amplification was mainly detected in carcinoma ex pleomorphic adenoma and myoepithelial carcinoma. For SDC, the frequency of ERBB2 and BRAF alterations were higher in cases with metastatic lesions than in those with primary lesions. Although 28.6% patients were offered recommended treatment options, only 6.8% received the recommended treatments. This study highlights the differences in genetic alterations among the histological types of SGC, with comprehensive genomic profiling tests revealing lower drug accessibility. These findings could contribute to the development of personalized treatment for patients with SGC.
Предметные рубрики MeSH
HumansSalivary Gland NeoplasmsMaleFemaleJapanAgedMiddle AgedAdultErb-b2 Receptor Tyrosine KinasesAged, 80 and overGenomicsCyclin-Dependent Kinase Inhibitor p16Tumor Suppressor Protein p53Carcinoma, Adenoid CysticDatabases, GeneticCarcinoma, DuctalProto-Oncogene Proteins B-rafYoung AdultAdenocarcinoma